118 related articles for article (PubMed ID: 37690970)
21. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.
Gandaglia G; Abdollah F; Schiffmann J; Trudeau V; Shariat SF; Kim SP; Perrotte P; Montorsi F; Briganti A; Trinh QD; Karakiewicz PI; Sun M
Prostate; 2014 Feb; 74(2):210-6. PubMed ID: 24132735
[TBL] [Abstract][Full Text] [Related]
22. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
Loriot Y; Fizazi K; de Bono JS; Forer D; Hirmand M; Scher HI
Cancer; 2017 Jan; 123(2):253-262. PubMed ID: 27648814
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.
Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Significance of Organ-Specific Metastases in Patients with Metastatic Upper Tract Urothelial Carcinoma.
Tufano A; Cordua N; Nardone V; Ranavolo R; Flammia RS; D'Antonio F; Borea F; Anceschi U; Leonardo C; Morrione A; Giordano A
J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36142956
[TBL] [Abstract][Full Text] [Related]
25. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.
Pond GR; Sonpavde G; de Wit R; Eisenberger MA; Tannock IF; Armstrong AJ
Eur Urol; 2014 Jan; 65(1):3-6. PubMed ID: 24120464
[TBL] [Abstract][Full Text] [Related]
26. Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant.
He M; Li JJ; Zuo WJ; Ji L; Jiang YZ; Hu XC; Wang ZH; Shao ZM
Cancer Med; 2019 Oct; 8(14):6212-6220. PubMed ID: 31373147
[TBL] [Abstract][Full Text] [Related]
27. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.
Mazzone E; Preisser F; Nazzani S; Tian Z; Bandini M; Gandaglia G; Fossati N; Montorsi F; Graefen M; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Eur Urol Oncol; 2019 Sep; 2(5):541-548. PubMed ID: 31411992
[TBL] [Abstract][Full Text] [Related]
28. Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients.
Deng K; Yang C; Tan Q; Song W; Lu M; Zhao W; Lou G; Li Z; Li K; Hou Y
Gynecol Oncol; 2018 Sep; 150(3):460-465. PubMed ID: 30001833
[TBL] [Abstract][Full Text] [Related]
29. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
Lee SS; Kim SB; Park SI; Kim YH; Ryu JS; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
Jpn J Clin Oncol; 2007 Nov; 37(11):829-35. PubMed ID: 17951334
[TBL] [Abstract][Full Text] [Related]
30. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
31. Incidence trends and survival of metastatic prostate cancer with bone and visceral involvement: 2010-2019 surveillance, epidemiology, and end results.
Kadeerhan G; Xue B; Wu XL; Chen WN; Wang DW
Front Oncol; 2023; 13():1201753. PubMed ID: 37601697
[TBL] [Abstract][Full Text] [Related]
32. Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.
Alumkal JJ; Chowdhury S; Loriot Y; Sternberg CN; de Bono JS; Tombal B; Carles J; Flaig TW; Dorff TB; Phung D; Forer D; Noonberg SB; Mansbach H; Beer TM; Higano CS
Clin Genitourin Cancer; 2017 Oct; 15(5):610-617.e3. PubMed ID: 28344102
[TBL] [Abstract][Full Text] [Related]
33. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ali A; Hoyle A; Haran ÁM; Brawley CD; Cook A; Amos C; Calvert J; Douis H; Mason MD; Dearnaley D; Attard G; Gillessen S; Parmar MKB; Parker CC; Sydes MR; James ND; Clarke NW
JAMA Oncol; 2021 Apr; 7(4):555-563. PubMed ID: 33599706
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis.
Leone BA; Vallejo CT; Romero AO; Machiavelli MR; Pérez JE; Leone J; Leone JP
Breast Cancer Res Treat; 2017 Feb; 161(3):537-548. PubMed ID: 27975154
[TBL] [Abstract][Full Text] [Related]
35. The prognostic analysis of different metastatic patterns in pancreatic neuroendocrine tumors patients: A population based analysis.
Wang S; Zhang J; Liu S; Zhang J
Medicine (Baltimore); 2019 Nov; 98(44):e17773. PubMed ID: 31689842
[TBL] [Abstract][Full Text] [Related]
36. A real-world, population-based study for the outcomes of patients with metastatic colorectal cancer to the liver with distant lymph node metastases treated with metastasectomy.
Abdel-Rahman O
J Comp Eff Res; 2022 Mar; 11(4):243-250. PubMed ID: 35075916
[No Abstract] [Full Text] [Related]
37. Prognostic Value of Site-Specific Metastases and Therapeutic Roles of Surgery and Chemotherapy for Patients With Metastatic Renal Pelvis Cancer: A SEER Based Study.
Chen WK; Wu ZG; Xiao YB; Wang QQ; Yu DD; Cai J; Zhou CF
Technol Cancer Res Treat; 2021; 20():15330338211004914. PubMed ID: 33929915
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of site-specific metastases and therapeutic roles of surgery for patients with metastatic bladder cancer: a population-based study.
Dong F; Shen Y; Gao F; Xu T; Wang X; Zhang X; Zhong S; Zhang M; Chen S; Shen Z
Cancer Manag Res; 2017; 9():611-626. PubMed ID: 29180897
[TBL] [Abstract][Full Text] [Related]
39. Impact of the primary tumor location on secondary sites and overall mortality in patients with metastatic upper tract urothelial carcinoma.
Collà Ruvolo C; Deuker M; Wenzel M; Nocera L; Würnschimmel C; Califano G; Tian Z; Saad F; Briganti A; Xylinas E; Verze P; Musi G; Shariat SF; Mirone V; Karakiewicz PI
Urol Oncol; 2022 Sep; 40(9):411.e1-411.e8. PubMed ID: 35902301
[TBL] [Abstract][Full Text] [Related]
40. Impact of Sites of Metastatic Dissemination on Survival in Advanced Gastroesophageal Adenocarcinoma.
Wang X; Espin-Garcia O; Jiang DM; Allen MJ; Ma LX; Bach Y; Chen EX; Darling G; Yeung JC; Wong RKS; Veit-Haibach P; Kalimuthu S; Jang RW; Elimova E
Oncology; 2022; 100(8):439-448. PubMed ID: 35764050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
